Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Limb fat mass increased significantly from baseline in patients switching from stavudine- or zidovudine-based regimens with clinical evidence of lipoatrophy at baseline[Moyle 2006; Fisher 2009; Tebas 2009]
- Several studies have demonstrated improvements in lipids when switching from abacavir/lamivudine to emtricitabine/tenofovir DF in combination with either efavirenz[Moyle 2015] or lopinavir/ritonavir[Behrens 2012] or different boosted PIs[Campo 2013]
- Two coformulated regimens that include tenofovir AF are important for switch strategies for patients with virologic suppression:
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Dyslipidemia, Fat Perturbations, Switch Strategies